Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma

NCT03013933 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03013933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03013933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
May 3, 2017
Completion date
May 24, 2022
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent hodgkin lymphoma, refractory hodgkin lymphoma